AUTHORS
Scott F. Huntington, MD, MPH, Rohit Ramanlal Mistry, MPharm, MSc, MBA2, Justin T. Puckett3, Sachin Kamal-Bahl, PhD4, Jennifer Prescott, PhD5, Siyang Leng, MD, MS6, Enrico De Nigris, MSc7, Jalpa Doshi, PhD8
AFFILIATIONS
1 Yale University, New Haven, Connecticut, United States
2 MSD UK Ltd, London, London, United Kingdom
3 COVIA Health Solutions, Ambler, PA, PA, United States
4 COVIA Health Solutions, Ambler, PA, PA, United States
5 Merck & Co Inc, Rahway, New Jersey, United States
6 Merck & Co Inc, Rahway, New Jersey, United States
7 MSD UK Ltd, London, London, United Kingdom
8 University of Pennsylvania Medicine Gas, Philadelphia, Pennsylvania, United States
ABSTRACT
Introduction
Covalent Bruton's tyrosine kinase inhibitors (cBTKis) such as ibrutinib (IBR), acalabrutinib (ACA), and zanubrutinib (ZAN) have transformed the treatment landscape of CLL/SLL. Although second-generation [2G] cBTKis like ACA and ZAN have demonstrated improved tolerability in clinical trials relative to first-generation [1G] IBR, real world evidence on their economic impact remains limited. High discontinuation rates seen in routine practice across cBTKis, particularly among older patients, may influence healthcare resource utilization (HCRU) and costs. Therefore, we set out to estimate the difference in costs and HCRU of cBTKi use and treatment discontinuation in an older population to understand the burden of disease.
Aims
To evaluate HCRU and healthcare costs among Medicare beneficiaries with CLL/SLL in the 12 months following initiation of first-line cBTKi therapy, across cohorts defined by cBTKis generation and treatment persistence patterns.
Methods
This retrospective cohort study used Medicare fee-for-service claims data (2017-2024) to identify elderly patients newly initiating first-line cBTKi therapy (IBR, ACA or ZAN). The index date was defined as the first observed cBTKi prescription fill. Eligible patients were required to have continuous enrolment in Medicare Parts A, B, and D for at least 36 months pre-index and at least 12 months post-index (or until death post-index), and at least one claim with a diagnosis of CLL/SLL in the pre- and post-index periods. Discontinuation was defined as having at least a 60-day continuous gap in treatment.
Cohorts were defined according to uptake of generation index cBTKi (1G IBR or 2G cBTKi) and persistence pattern (continuous users, with no evidence of treatment discontinuation during the observation period and early discontinuers, who discontinued cBTKi therapy or died within the first 12 months of follow-up).
Outcomes included all-cause HCRU and healthcare costs, stratified into medical and pharmacy components. Statistical significance and confidence intervals on HCRU were assessed using Z-tests based on the natural logarithm of the Incidence Rate Ratios (IRRs), assuming Poisson-distributed event counts. Additionally, Z-tests were applied to assess the differences in mean costs. Analyses evaluated the outcomes difference in: (1) cBTKi generation (2G cBTKis vs. 1G IBR) and (2) treatment persistence (early discontinuation vs. continuous use).
Results
A total of 6,192 eligible patients were identified (mean age 78.6 ± 6.5 years; 44% female), including 2,574 treated with IBR and 3,618 treated with 2G cBTKis (ACA N=2,724 and ZAN N=894). Median follow-up was 26.7 months (IQR: 16.4, 41.6).
In the 12 months following cBTKi initiation, relative to IBR, 2G cBTKis were associated with lower HCRU, including fewer ER visits (IRR=0.84, 95% CI 0.79-0.89, p<0.001), hospitalizations (IRR=0.88, 95% CI 0.83-0.93, p<0.001), and home health visits (IRR=0.91, 95% CI 0.85-0.97, p=0.005), as well as lower total healthcare costs ($181,938 vs $186,120, cost difference: [95% CI] = - $4,182 [ -8137, -227], p=0.038).
In contrast to continuous users (N=2,238), early discontinuers (N=2,619) experienced higher HCRU in the 12 months following cBTKi initiation, including increased ER visits (IRR=1.83, 95% CI 1.70-1.96, p<0.001), hospitalizations (IRR=2.49, 95% CI 2.32-2.68, p<0.001) and home health visits (IRR=1.86, 95% CI 1.73-2.01, p<0.001). Nevertheless, total healthcare costs were lower ($151,585 vs $200,627, cost difference [95% CI] = -49,043 [-53,282, -44,803], p<0.001), as reductions in pharmacy costs associated with treatment discontinuation ($90,262 vs $172,217, cost difference [95% CI] = -$81,956 [-85,349, - $78,562], p<0.001) more than offset the increase in medical spending ($61,323 vs $28,410, cost difference [95% CI] = $32,913 [$30,081, $35,745], p<0.001).
Conclusions
2G cBTKis were associated with lower HCRU and total healthcare costs in the 12-months following cBKTi initiation, compared with IBR. Early discontinuation increased medical resource use but reduced total costs due to lower drug exposure. Future research integrating clinical outcomes may further contextualize the cost-effectiveness implications of treatment discontinuation patterns.
DISCLOSURES
Scott F. Huntington, MD, MPH: AstraZeneca - Honoraria; Genentech - Honoraria; BeOne - Research Funding; Nurix Therapeutics - Research Funding; AbbVie - Research Funding; Merck & Co., Inc. - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)